Category: Cancer Research

Eric Lefkofsky Attack on Cancer

Eric Lefkofsky’s wife was diagnosed with breast cancer. He accompanied his wife on her doctor visits. However, he discovered her treatments were great, but the oncologist didn’t use technology. For instance, his wife had a test done and her oncologist didn’t have the centralized database to see the results. Instead, he requested the results which took up to 3 weeks to come in. Here he is Eric Lefkofsky with at least 20 years’ experience in technology. Needless to say, this led him to create Tempus Labs company. The purpose of the company is to gather personal data about the cancer patient and store it in one place. He hopes to equip the oncologist with the best technology to aid diagnosing and treating patients.

Lefkofsky’s whole idea of centralized data is innovative. The oncology field as a whole is not tech savvy. Tempus Labs not only gather information about the cancer patients, but it includes clinical data. The data include outcomes to specific treatment such as DNA and RNA. DNA sequencing is also used for personized medicine. This is great to have in one location, so the doctor can devote more time to the patient. The vast data in one location will provide the oncologist the tool to better diagnose the patient. The doctor will see what type of treatment worked efficiently for which types of cancer.

Although Eric Lefkofsky is an entrepreneur he’s an avid philanthropist first. He and his wife founded the Lefkofsky Family Foundation. The foundation is active in supporting advanced education, arts, culture, human rights, and medicine. He is also a pledge giver to the community. He sits on the Board of Trustees of the Lurie Children’s Hospital of Chicago. The Tempus O plans to extract pertinent information from disorganized data about cancer patients. In hopes of making the data clearer and easy for physicians to use.

Eric Lefkofsky info:

Clay Siegall’s Passion For Conducting Cancer Research

In the last decade, Seattle Genetics made significant strides in the field of cancer research. Today, the company has recruited some of the leading researchers and scientists to undertake comprehensive studies on cancer and aging. The firm started as a small agency. With its continued progress in developing viable cancer therapies, Seattle Genetics has managed to expand the scope of its research to include aging-related diseases. Within five years of operations, Seattle Genetics’ stock price had tripled, indicating the firm’s impact in the industry.

Clay Siegall heads Seattle Genetics. Since he started his profession in biomedical studies, Clay has always been interested in improving the lives of cancer patients. He is a graduate of George Washington University where he earned his PhD in Genetics. He started his career at Bristol-Meyers Squibb Pharmaceuticals Research Institute by working as a senior research investigator. He rose through the ranks to become a principal scientist. Later, he joined the National Cancer Institute where he worked as a biotechnology and staff fellow.

Over the years, Siegall has helped the company to make successful breakthroughs in cancer research. Clay has a genuine desire to assist cancer patients. It is for this reason that Dr. Clay has zeroed in on developing viable cancer drugs to lengthen the lives of cancer patients. Under Siegall’s visionary leadership, the company was able to develop the first antibody-drug conjugates known as ADCETRIS.

About Clay Siegall

Clay Siegall is a revered scientist. Over the years, he has specialized in targeted cancer therapies. Clay is one of the founders of Seattle Genetics, which was established in 1998. He serves as the CEO and president of company. In addition, Clay is the chairman of the board. He founded the company on the foundation of rigorous research, scientific innovation, drug development and passion for assisting patients. Presently, Siegall is leading the company in developing a pipeline of proprietary ADCs for cancer treatment.

Over the years, Clay has helped Seattle Genetics to enter into several strategic partnerships with GlaxoSmithKline, AbbVie, and Genentech for its ADC technology. These licenses have generated over $350 million. Siegall has also guided the firm in capital-raising activities. To this end, he has secured more than $1.2 for the corporation through private and public financing.